
## **Cell-Free Protein Synthesis Scale-Up and GMP Production of Protein Biotherapeutics** for Clinical Trials


James Zawada, Julie Hang, Robert Kiss, Sutro Biopharma, South San Francisco, CA

## BACKGROUND


- Traditional expression systems require several days or weeks for each process cycle. This slows down process development and increases the time to clinic for new product candidates
- In addition, these systems are limited to the 20 canonical amino acids which constrains the ability to produce next-generation therapeutics like antibody-drug conjugates
- Sutro Biopharma has developed a cell-free protein synthesis process, XpressCF+<sup>™</sup>, that capitalizes on the speed and flexibility of cell-free systems to accelerate product and process development
- XpressCF+<sup>™</sup> further enables GMP production of nonnatural amino acid containing antibodies at a clinically relevant scale



Schematic of clinical candidate STRO-002 production by XpressCF+ $^{TM}$ . The incorporation of the non-natural amino acid (pAMF) enables sitespecific conjugation of the linker-warhead payload.



1000



The world's first GMP cell-free manufacturing facility



Continuous culture bioreactor for the cell-free extract (XtractCF<sup>™</sup>) production



